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Abstract 24 
Canine mast cell tumours (MCT) staging is commonly performed using abdominal 25 
ultrasonography and fine needle aspiration cytology of masses, lymph nodes, hepatic and 26 
splenic parenchyma. Computed tomography (CT) is used for abdominal and thoracic or 27 
whole-body imaging in staging MCT in the authors’ institution enabling to evaluate multiple 28 
body areas in one exam. The purpose of this study was to compare the CT exams acquired 29 
for staging of mast cell disease to their subsequent liver and spleen cytology findings.  30 
Medical records of dogs with primary MCT that underwent abdominal CT and 31 
concurrent liver and spleen aspirates were reviewed. The CT exams were evaluated for 32 
attenuation, size and margination of the liver and spleen. The relationship between CT 33 
findings and cytology results was analysed.  34 
Forty-nine dogs matched the inclusion criteria: 5/49 dogs with cutaneous MCT were 35 
positive for metastasis from liver and/or spleen aspirates. Of the 5 dogs with cytological 36 
evidence of liver or spleen metastasis, 4 had normal CT liver attenuation and size, one dog 37 
had concurrent primary hepatocellular neoplasia, 4 dogs had abnormal splenic parenchyma 38 
dogs (2 nodular, 2 diffuse heterogeneity) and one dog had a normal attenuation of the spleen. 39 
In 4 dogs, the spleen was subjectively enlarged.  40 
CT evaluation of the liver showed no consistent pattern associated with mast cell 41 
metastasis and did not predict cytology results. Splenic enlargement more commonly 42 
coincided with mast cell metastasis. Sampling of the liver and spleen remains to be 43 
considered in the absence of abnormal CT findings for full staging. 44 
 45 
 46 
 47 
  48 
Introduction 49 
Mast cell tumours (MCT) are recognised as one of the most common canine malignant neoplasms, 50 
accounting for 16-21% of canine skin tumours.1 MCT can vary greatly in their biological behaviour.2 51 
and range from benign to highly malignant tumours characterised by local invasion and frequent 52 
metastasis is encountered. Alongside cytological and histological techniques, diagnostic imaging is 53 
used for staging of MCT according to published guidelines.3,4 Histological grading has been 54 
established as the strongest prognostic indicator.1,3 Identifying local recurrence, regional and distant 55 
metastasis is important when evaluating the biological behaviour of suspected high grade MCT to 56 
provide accurate prognostic information and guide treatment. 57 
Abdominal ultrasonography has been recommended to assess the liver and spleen for evidence of 58 
metastasis for staging of confirmed Kiupel high grade and Patnaik grade II-III MCT and those with 59 
confirmed nodal metastasis.1,4,5 Sampling of any abnormal and also generic parenchyma for 60 
cytological examination is performed to confirm or rule out the presence of metastasis in these 61 
organs. In our institution, computed tomography (CT) is routinely used for whole body staging of 62 
confirmed MCT and also to aid surgical planning. Similarly, CT has recently been used more 63 
frequently for staging of various neoplasms due to the increased sensitivity of identifying potential 64 
metastatic lesions, as well as assessing the extent and infiltrative characteristics of the primary 65 
tumours as well as response to therapy for systemic neoplasia such as lymphoma.6-10 CT exams 66 
show a greater diagnostic accuracy for predicting hepatic lesions when compared to ultrasound 67 
exams, although the diagnostic specificity for any hepatic neoplastic lesions remains unreliable.11,12  68 
These principles could be applied to mast cell neoplasia though a comparison of CT exam findings 69 
to cytological or histological liver and spleen samples has not been evaluated.  70 
We hypothesize that CT exam findings will predict metastatic invasion of liver and spleen in dogs 71 
with positive cytology examination results of these organs. 72 
  73 
Material and methods  74 
Selection and description of subjects 75 
For this original investigation, a retrospective review of the medical records was conducted at the 76 
Queen Mother Hospital for Animals from May 2012 to December 2016 for canine patients that 77 
were diagnosed with MCT and had an abdominal pre- and post-contrast CT exam and subsequent 78 
ultrasound guided liver and spleen fine needle aspirates for disease staging. The project was 79 
approved by the local ethical review board (URN SR2017-1485). Patients were included if 80 
cytologic examination from the liver, spleen or both organs was available. The decision to carry 81 
out liver and spleen fine needle aspirates was independent of the CT exam findings according to 82 
the institutional protocol. Exclusion criteria included incomplete pre- and post-contrast CT 83 
examination or incomplete clinical records. Patient data recorded included signalment, body 84 
weight, location of primary tumour, patient management prior to referral, date of CT and 85 
occurrence of repeat CT exams, histological grade of MCT, presence of lymph node metastasis 86 
determined by cytology from fine needle aspirate or histology after excision, liver and spleen 87 
cytology results and patient management. Histological grade was standardised into an 88 
encompassing 2-tier grading system based on reported board certified pathologist assessment 89 
using the Kiupel system, where stated, for cutaneous mast cell tumours and otherwise using 90 
previously published criteria for grading of non-cutaneous MCT.1,4,13,14 Regional lymph node 91 
metastasis was suspected according to cytological and histological criteria used in previous 92 
studies.15,16 93 
Computed tomography examinations and evaluation 94 
A 16 MDCT unit (MX 8000 IDT, Philips Medical Systems, Cleveland, OH, USA) was used for the 95 
CT examinations and 2ml/kg iohexol 300mgI/ml (Omnipaque 300, GE Healthcare, Oslo, Norway) 96 
was injected intravenously for the post contrast exams using a power injector (Stellant, Medrad Inc., 97 
PA) at 2ml/s (maximum pressure 150 PSI); image acquisition for the post contrast exam was 98 
initiated 60s post contrast injection. Helical scan mode at 120kVp, 100-140mA was used with a 99 
medium frequency reconstruction algorithm; reconstruction slice thickness was selected based on 100 
patient size and ranged from 2-3mm with continuous slices reconstructed.  101 
CT exams for dogs that had liver and spleen aspirates were first reviewed by the first author and 102 
then a consensus review was carried out with a board-certified radiologist using a commercially 103 
available DICOM viewer (OsiriX 64bit, Pixmeo SARL, 266 Rue De Berne, CH1233 Bernex, 104 
Switzerland). Both authors were unaware of the subsequent fine needle aspirate results while 105 
reviewing the CT exams.  106 
Pre- and post-contrast CT studies were reviewed using a soft tissue window (window level 107 
40 HU, window width 350 HU). The liver and spleen were assessed for size and margination, overall 108 
parenchymal attenuation and the presence of any nodular or mass lesions including the post-109 
contrast attenuation pattern of these lesions. The liver and spleen were categorised as either 110 
subjectively (1) normal sized or (2) enlarged by assessment of shape and margination. The 111 
attenuation pattern was categorised into 3 groups: (1) homogeneous, (2) diffusely heterogeneous 112 
and (3) focally heterogeneous, nodular or mass. Dogs that had small hypoattenuating cysts in the 113 
liver parenchyma were not categorised as having a nodular pattern as long as the rest of the liver 114 
parenchyma was homogeneous as these were considered incidental findings.17 The hepatic and 115 
splenic lymph nodes, where visible, were measured along the maximal short axis in transverse plane 116 
using the measuring tool of the viewing software and their subjective attenuation pattern was 117 
recorded. Any other abnormal abdominal CT findings were noted. If patients had multiple CT exams 118 
and subsequent aspirates, these were included as separate data sets. 119 
The liver and spleen aspirates following the CT exam were recorded as (1) positive or (2) 120 
negative for mast cell tumour metastasis as noted on the cytology report from our institutions in-121 
house team of board-certified clinical pathologists. The criteria used to define evidence of metastasis 122 
included large numbers and/or clusters of well-differentiated mast cells or the presence of mast cells 123 
with an atypical morphology.5 Cytological findings of mastocytosis where mast cell metastasis could 124 
not be confirmed or ruled out, and was therefore inconclusive, were accounted for as negative for 125 
the purposes of the statistical analysis. 126 
 127 
Statistical analysis 128 
Clinical and case data was presented using descriptive statistics. Means and standard deviations 129 
were calculated for all normally distributed variables, medians and ranges for any skewed variables. 130 
Normality was visually assessed from the frequency distribution on histograms formulated from the 131 
collected data. Cases were grouped according to presence of metastasis based on the cytological 132 
evaluation. Those cases that were positive for metastasis were described in detail and analysed for 133 
any common findings in their CT exams. Statistical analysis was carried out using a commercially 134 
available statistics software (SPSS Statistics for Macintosh, Version 24.0., IBM corp, Armonk, NY, 135 
USA). Pearson Chi-squaredFishers Exact tests were used to test the difference between categorical 136 
variables of the groups (CT characteristics for the 2 groups; positive and negative for liver and spleen 137 
metastasis) and independent t–tests were used to test the difference between parametric 138 
continuous variables of the groups (splenic and hepatic lymph node size). Assumptions for Pearson 139 
Chi-squaredFisher’s Exact test were met when the variables tested were independent of each other 140 
and were recorded as nominal categorical variables. 141 
 142 
  143 
Results 144 
Subjects and tumour characteristics 145 
Patient records for 78 CT exams were identified matching the initial search criteria. Patients records 146 
of 57 pre- and post-contrast CT exams with subsequent liver and spleen fine needle aspirates for a 147 
total of 49 patients were included in the analysis. 21 CT exams were excluded according to the 148 
defined exclusion criteria. There were 26/49 (53%) male dogs (13/26 (50%) neutered) and 23/49 149 
(47%) female dogs (19/23 (83%) neutered). Labrador retriever was the most prevalent breed with 150 
12/49 (24%) patients; there were 10/49 (20%) cross breeds, 3/49 (6%) of each of the following 151 
breeds: Staffordshire Bull Terrier, Pug and Bull Mastiff, 2/49 (4%) of each of the following breeds: 152 
Golden Retriever, Boxer, Chihuahua and Shar Pei and 1/49 (2%) of each of the following breeds: 153 
Beagle, English Springer Spaniel, French bulldog, German Short Haired Pointer, German Long 154 
Haired Pointer, Jack Russell Terrier, Husky, Weimaraner, Welsh Springer and West Highland White 155 
Terrier. The median weight at presentation was 29.7kg (range 3.1-57.8kg). Median age at time of 156 
CT exam was 8 years of age (range 2 – 15 years). 157 
 Cutaneous MCT were the most prevalent, accounting for 33/49 (67%) of the cases, followed 158 
by 9/49 (18%) subcutaneous MCT, 5/49 (10%) mucosal or mucocutaneous MCT, 1/49 (2%) jejunal 159 
and 1/49 (2%) rectal wall MCT. The tumours had been noted to be present for a mean of 4.4 months 160 
(SD +/- 5.7) prior to presentation. 21/49 (43%) patients had a complete excision or attempted 161 
complete excision of the mass prior to referral. 31/49 (63%) of patients had histologically low grade 162 
MCT and 18/49 (34%) had high grade MCT by pathologist assessment. 17/49 patients (39%) had 163 
suspected regional lymph node metastasis based on cytology or histology after surgical biopsy. Of 164 
those dogs that had evidence of lymph node metastasis, 9/17 (53%) were diagnosed with low grade 165 
MCT and 8/17 (47%) with high grade MCT.  166 
CT exam characteristics for the total study population 167 
Overall, the liver parenchyma was homogeneous in 40/57 (70%) CT exams, diffusely 168 
heterogeneous in 5/57 (9%) CT exams and had focal heterogeneity, nodule or mass lesion in 12/57 169 
(21%) exams (Table 2). 5/57 (9%) exams had small singular hypoattenuating liver cysts but 170 
otherwise homogeneous parenchyma and were classified overall to have a homogeneous liver. The 171 
liver was considered subjectively normal in size in 33/57 (58%) exams and subjectively enlarged in 172 
24/57(42%) exams.  173 
The splenic parenchyma was homogeneous in 36/57 exams (63.2%), diffusely 174 
heterogeneous in 7/57 exams (12.3%) and had focal heterogeneity/nodular/mass lesions in 14/57 175 
exams (24.6%) (Table 3). Of the 14 exams that were categorised as having focal heterogeneity, 176 
nodule or mass, 7 (50%) had hyperattenuating nodules (Fig. 4). The spleen was subjectively normal 177 
in size in 36/57 exams (63.2%) and subjectively enlarged in 21/57 exams (36.8%).  178 
 The mean left and right hepatic lymph node size was 6.6mm (+/- SD 2.7mm) and 5.8 mm (+/- 179 
SD 1.9mm) respectively across the maximal short axis excluding those cases where the hepatic 180 
lymph nodes could not be visualised. The left and right hepatic lymph node could not be visualised 181 
in 1/57 (1.8%) exams, the right hepatic lymph node could not be visualised in 5/57 (8.8%) exams. 182 
In the former exam, there was an area of heterogenous soft tissue where the hepatic lymph nodes 183 
were expected to be located but the borders could not be well defined. Where at least one lymph 184 
node could be examined (56 exams), attenuation for the hepatic lymph nodes was homogeneous 185 
in 32/56 (57.1%) exams and heterogeneous in 18/56 (32.1%) exams. The splenic lymph nodes were 186 
identified in 52/57 (91%) exams, and were not visible in 5/57 (9%) exams. The mean splenic lymph 187 
node size was 5.1mm (+/- SD 2.7mm). The splenic lymph node attenuation was homogeneous in 188 
47/52 (90.4%) cases and heterogeneous in 5/52 (9.6%) exams. Hepatic and splenic lymph node 189 
size data was normally distributed. 190 
After 54/57 (95%) CT exams, both liver and spleen aspirates were performed, after 2/57 (4%) 191 
CT exams only liver aspirates and after 1/57 (2%) CT exam only splenic fine needle aspirates were 192 
performed. All cytology interpretations were carried out in-house by a board-certified pathologist. In 193 
43/57 (75%) cytologic examinations, the liver and spleen were negative for evidence of mast cell 194 
metastasis. In 9/57 (16%) exams, findings were inconclusive by either having suspected reactive 195 
mastocytosis or mast cell metastasis could not be confirmed or ruled out and were therefore 196 
accounted for as negative. In 5/57 (9%) cytological examinations of 5 different cases mast cell 197 
metastasis was confirmed. No repeat CT examinations were positive for liver and spleen metastases 198 
on the subsequent fine needle aspirates. A flow chart summary of the CT exams and corresponding 199 
positive and negative cytological examination is given in Figure 1. 3/5 (60%) exams were positive 200 
for metastatic disease on both liver and spleen fine needle aspirates, 2/5 (40%) were positive on 201 
splenic aspirates alone and one of these patients did not have liver aspirates performed, no exams 202 
were positive on liver aspirates alone.  203 
CT exam characteristics for patients with cytologically confirmed liver/spleen metastasis  204 
Dogs with cytologically confirmed metastatic disease ranged from 8-10.5 years at the time of exam. 205 
3/5 patients had high grade and 2/5 had low grade MCT. 2/5 patients had evidence of regional lymph 206 
node metastasis confirmed by cytology or histology prior to their CT exam summarised in Table 1.  207 
4/5 patients had normal liver attenuation and size on CT. 1/5 had a large heterogeneous 208 
hyperattenuating mass with otherwise diffuse heterogeneity of the liver parenchyma and a grossly 209 
enlarged liver, which did not have evidence of metastasis and was diagnosed as either a 210 
hepatopathy or possible well differentiated hepatocellular neoplasia.  211 
2/5 exams showed focal hypoattenuating nodular splenic changes (Fig. 2), 2/5 exams 212 
diffusely heterogeneous splenic parenchyma (Fig. 3) and 1/5 exam a normal attenuation of the 213 
spleen. 4/5 exams showed subjectively enlarged splenic parenchyma. The CT findings for the 214 
patients with confirmed liver and spleen metastasis are summarised in Table 4. 1/5 patient had 215 
imaging findings consistent with chronic renal disease on CT, otherwise the CT exams were 216 
unremarkable. 2/5 exams that had positive liver metastasis had hepatic lymph nodes larger at cross-217 
sectional diameter than the mean for the total population (Table 4.) 2/5 exams that had positive 218 
splenic metastasis had splenic lymph nodes larger at cross-sectional diameter than the mean for 219 
the total population (Table 4.) 220 
In the exam with liver mass, the hepatic lymph nodes could not be identified discreetly but it 221 
was suspected that they were part of a heterogeneous ill-defined soft tissue area adjacent to the 222 
portal vein. Of the five exams positive for liver or spleen metastasis, the mean left hepatic lymph 223 
node size was 5.58mm (+/- S.D. 3.72), mean right hepatic lymph node size was 5.38mm (+/- S.D. 224 
3.57) and mean splenic lymph node size was 5.26mm (+/- S.D. 1.79). 225 
  226 
CT exam characteristics for patients with no evidence of liver/spleen metastasis on cytologic 227 
examination. 228 
52/57 (91%) CT exams had subsequent liver and spleen cytologic examination negative for 229 
mast cell metastasis. Of these CT exams, 36/52 (69%) had homogeneous liver parenchyma, 5/52 230 
(10%) had diffusely heterogeneous liver parenchyma and 11/52 (21%) and focal 231 
heterogeneity/nodules/masses. The liver was subjectively enlarged in 23/52 (44%) exams. 35/52 232 
exams (67%) showed homogeneous and 5/52 (10%) diffusely heterogeneous splenic parenchyma. 233 
12/52 (23%) exams showed focal heterogeneity/nodules/masses, of these 7/12 exams had discrete 234 
contrast enhancing nodules. The spleen was subjectively enlarged in 17/52 exams (33%).  235 
Statistical analysis 236 
There was no statistically significant difference between liver attenuation (P=0.7561), liver 237 
size (P=0.385295), splenic attenuation size (P=0.05662) as well as hepatic or splenic lymph node 238 
size (P=0.692 and P=0.394 respectively) between the exams that had positive and negative 239 
cytologic evaluation of the liver and spleen for MCT metastasis. Dogs positive for MCT metastasis 240 
in the spleens had significantly larger spleens more heterogeneous or nodular spleens on CT exam 241 
(P=0.0436).  242 
 243 
  244 
Discussion 245 
Mast cell tumours are well documented to spread to the regional lymph nodes, liver, spleen and 246 
bone marrow.2,18 Staging of mast cell disease remains an important process in the development of 247 
treatment protocols, to monitor progression of the disease and to provide prognostic information for 248 
the owners. 249 
Labradors and mixed breed dogs were the most prevalent breeds in this study, which 250 
correlates with previous published work on mast cell tumours.2,4,19 Mast cell neoplasia was 251 
diagnosed primarily in middle aged to older dogs in our study population which is consistent with 252 
previous studies.2,20,21 Most patients had cutaneous MCT (67.3%), although subcutaneous, 253 
mucocutaneous and other origins were also represented in our study population. Interestingly, all 254 
dogs that had cytology results positive for metastasis had cutaneous MCT (Table 1), despite 255 
mucosal, mucocutaneous, gastrointestinal and visceral MCT being reported to show biologically 256 
more aggressive behaviour, often metastasizing to regional lymph nodes.20,21 63% of all MCT’s were 257 
considered low grade based on histology. This proportion was difficult to compare to previous 258 
studies as a 3-tier system has previously been used most commonly, although the finding was 259 
consistent with two previous studies that reported a prevalence of low grade MCT’s of 60-74%.22-24 260 
The authors suspect that the prevalence of high grade MCT in this study is greater than compared 261 
to general practice, which likely reflects the greater proportion of patients with low grade MCT not 262 
being selected for referral or further staging.  263 
In this study population, CT exams obtained prior to ultrasound guided fine needle aspiration 264 
did not provide a repeatable or specific pattern in target organs to predict the presence of metastasis. 265 
Based on the result of this study, liver and spleen fine needle aspirates should be considered to 266 
assess for metastatic mast cell disease in these organs, when clinical suspicion is highest, as the 267 
CT findings are not specific for metastasis. The CT exam may guide the targeting of abnormal 268 
parenchymal areas in addition to generic tissue sampling. Despite low grade tumours being included 269 
in this study, the findings are consistent with the recommendation made in previous studies that 270 
aspirates for cytological examination should always be taken even in the absence of 271 
ultrasonographic changes to the liver and spleen for Patnaik Grade II and III tumours with aggressive 272 
clinical characteristics.24 It has been shown that dogs with evidence of liver and splenic mast cell 273 
infiltration have shorter survival times, therefore it is important to rule out infiltration of these organs 274 
for determining prognosis.5  275 
Patients with metastatic mast cell tumours in the liver and spleen could show a varied pattern 276 
on CT exams including mild subjective enlargement of the organs, homogeneous, nodular patterns 277 
and diffuse heterogeneity of the parenchyma versus a normal appearance of the organs (Figure 2, 278 
3). There is someThe results suggest suggestion that mast cell metastasis could cause multifocal 279 
hypoattenuating lesions of the splenic parenchyma as seen on CT exams (both diffuse 280 
heterogeneity and nodular/focal heterogeneity was significant, P<0.05) but this could not be 281 
confirmed statistically due to thethere was a low number of patients with cytology results positive for 282 
metastatic disease and more studies with a higher number of cases positive for metastatic disease 283 
would be needed. Splenic enlargement was present in 4 of the positive cases. While this could be 284 
suggestive of diffusely infiltrative metastasis, splenic enlargement is a common finding due to 285 
congestion because of sedation or general anaesthesia, used for CT exams in this study.  286 
The hepatic and splenic lymph nodes evaluated in this study were consistently measured at 287 
around 5mm on short axis diameter, which is considered within the normal range.25 The appearance 288 
of presumptively normal abdominal lymph nodes on CT has prior been published, though size, 289 
shape as well as the number of organ specific lymph nodes seen may vary between patients.25 Even 290 
with a measurable increase in size, without cytological or histological confirmation of metastasis to 291 
these lymph nodes, enlargement cannot be reliably attributed to either neoplasia, inflammatory or 292 
immune-mediated stimulation. 293 
Only 2 of the 5 cases with positive liver/spleen metastasis had cytologically or histologically 294 
confirmed regional lymph node metastasis (Table1), although metastasis was suspected in the 3 295 
remaining patients due to the presence of lymphadenomegaly on CT exam. Therefore, it is possible 296 
that all 5 cases with positive liver/spleen metastasis had regional lymph node metastasis consistent 297 
with previous studies.26  Ultrasound guided sampling of the regional lymph node was not performed 298 
in some patients due to limited accessibility.  299 
Two of the low-grade tumours were positive for liver and/or spleen metastasis (Table 1), 300 
which is conflicting with previous studies, which state that histological grade is the best predictor of 301 
metastatic potential and therefore prognosis. Multiple explanations for this should be considered: It 302 
is possible that dogs may have multiple MCT,2,4,27 therefore it is possible that a high grade tumour 303 
could have been present elsewhere on the body unnoticed. Currently, veterinary pathologists use 304 
two systems for histologically grading canine cutaneous mast cell disease according to published 305 
literature due to multiple variation and discrepancies between pathologists.13 These include the 3-306 
tier Patnaik grading system and the 2-tier Kiupel grading system.14,28 Non-cutaneous MCT are 307 
graded by pathologists by histological guidelines, although there is currently no evidence of 308 
correlation with prognosis.4  It has been shown that there can be significant variation of assigned 309 
histological grades by different pathologists, therefore certain level of variability could have been 310 
present in our study, however the use of the 2-tier Kiupel system has likely minimized this, as 311 
demonstrated by previous studies. 13,22,29 Finally, MCT are known to show intermediate 312 
differentiation4 and therefore can be unpredictable in their behaviour while classified as low grade, 313 
or carry proliferative markers that indicate more aggressive biological behaviour.30  314 
Ultrasound-guided liver and spleen fine needle aspirates are often taken despite normal 315 
findings on ultrasound exams, to cytologically identify infiltrative disease. Cytological examination of 316 
these aspirates to confirm metastasis is hindered by a grey zone between obvious positive and 317 
negative results as it can be difficult to differentiate between metastatic versus non-metastatic 318 
populations of mast cells when numbers are increased.1,15,24,31 Therefore, in certain cases it can be 319 
controversial to diagnose metastasis based on cytological examination alone as mastocytosis in 320 
these organs can also be seen with non-neoplastic, reactive or immune mediated conditions as 321 
suggested by previous studies.32 As a result, imaging alongside cytological assessment will likely 322 
continue to play an important role in staging mast cell tumours. The exact location of the fine needle 323 
aspirate samples taken was not always recorded in the medical records and may therefore not 324 
distinctly correlated with the abnormal region seen on CT, though CT exams are regularly reviewed 325 
by a board-certified radiologist in our institution prior to sampling. For the spleen, sampling location 326 
may be difficult to verify due to differing positions of recumbency possibly inducing shift of organ 327 
position between CT exam and ultrasound exam. 328 
Cytological assessment of liver and spleen were negative for metastasis in 52/57 exam. Despite 329 
approximately one third of the negative CT exams showing abnormal hepatic or splenic tissue 330 
attenuation, a low number of metastatic disease cases were confirmed on cytological examination. 331 
This indicates that the CT examinations do show a gamut of unrelated benign or malignant changes, 332 
making differentiation from metastatic disease challenging.17,33  In addition, approximately 3% of 333 
patients can present with multiple primary neoplasms.34  334 
Focal contrast enhancing nodules in the spleen have been reported before as likely benign 335 
extramedullary haematopoesis and nodular hyperplasia, related to the high vascularity of lymphoid 336 
hyperplastic tissue, and malignant change is more likely to be hypoattenuating both pre and post 337 
contrast,17,33 otherwise nodular changes could represent myelolipoma, haemangiosarcoma and 338 
other neoplasia.17  339 
The limitations of this study reflect its retrospective nature. The subjective nature and varying criteria 340 
of the pathology reports could also have resulted in inaccuracies. Assessment of the CT scans was 341 
subjective by the primary author and therefore resulted in bias; this was controlled as best possible 342 
using the consensus review with a board-certified radiologist. Categorisation of liver and spleen 343 
enlargement was based on subjective evaluation of size and margination. Animals undergoing 344 
steroid treatment were not consistently reported in the clinical records, therefore the effect this may 345 
have had on the result could not be assessed and is a recognised limitation of the study. 346 
Parenchymal attenuation could have been affected by mild variation in contrast injection timing in 347 
relation to CT exam acquisition especially depending on patient size. The exams were routinely 348 
acquired 60s post contrast injection independent of patient size and haemodynamic state and 349 
expected parenchymal enhancement was seen on the CT examination, hence this is thought to 350 
have low impact on the results of this study. Lymph nodes were occasionally difficult to distinguish 351 
from adjacent soft tissue structures. Measurements were applied in the transverse plane only for 352 
consistency. A main limitation of this study is the low number of cases with confirmed hepatic or 353 
splenic metastasis bases on cytological evaluation, therefore a larger population of patients would 354 
be need for a more conclusive evaluation.  355 
This study did not confirm the hypothesis that CT exam findings of the liver and spleen of patients 356 
positive for liver and spleen MCT metastasis had similar characteristics, therefore sampling of the 357 
liver and spleen by ultrasound guided FNA remains indicated. Positive samples were found in 358 
organs with normal CT appearance and this result will influence prognosis and course of treatment. 359 
Abnormal findings of the liver and spleen were detected regularly on CT exam that should trigger 360 
incentive to sample for cytological examination and can help guide location for sampling of abnormal 361 
and normal appearing tissue. In addition, a global overview of the abdomen is gained, allowing for 362 
thorough assessment of the regional lymph nodes and other abdominal structures, that may prompt 363 
further tissue sampling if abnormalities are found. Therefore, the use of CT in the detection and 364 
staging of primary MCT will likely continue to prove useful. 365 
 366 
  367 
Authorship contributions: 368 
Category 1:  369 
a) Conception and design 370 
Randi Drees, Jonathan R Hughes 371 
b) Analysis of data 372 
 Jonathan R Hughes, Randi Drees, Balazs Szladovits 373 
c) Interpretation of data 374 
 Jonathan R Hughes, Randi Drees, Balazs Szladovits 375 
Category 2:  376 
a) Drafting the article 377 
Jonathan R Hughes 378 
b) Revising it critically for important intellectual content 379 
Randi Drees, Balazs Szladovits 380 
Category 3)  381 
Final approval of the version to be published 382 
 Jonathan R Hughes, Randi Drees, Balazs Szladovits 383 
 384 
  385 
References 386 
 387 
1. Blackwood L, Murphy S, Buracco P, et al. European consensus document on mast cell tumours in dogs and 388 
cats. Vet Comp Oncol.  2012;10(3):e1-e29.  389 
2. London CA, Thamm DH. Mast Cell Tumors. In: Withrow and MacEwen's Small Animal Clinical Oncology. 390 
Elsevier; 2013:335-355. 391 
3. Murphy S, Sparkes AH, Blunden AS, Brearley MJ, Smith KC. Effects of stage and number of tumours on 392 
prognosis of dogs with cutaneous mast cell tumours. Vet Rec. 2006;158(9):287-291.  393 
4. Welle MM, Bley CR, Howard J, Rüfenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical 394 
features, pathology and treatment. Vet Dermatol 2008;19(6):321-339.  395 
5. Stefanello D, Valenti P, Faverzani S, et al. Ultrasound-Guided Cytology of Spleen and Liver: A Prognostic Tool 396 
in Canine Cutaneous Mast Cell Tumor. J Vet Intern Med. 2009;23(5):1051-1057.  397 
6. Pollard RE, Fuller MC, Steffey MA. Ultrasound and computed tomography of the iliosacral lymphatic centre in 398 
dogs with anal sac gland carcinoma. Vet Comp Oncol. 2017;15(2):299-306.  399 
7. Iwasaki R, Murakami M, Kawabe M, et al. Metastatic diagnosis of canine sternal lymph nodes using computed 400 
tomography characteristics: A retrospective cross-sectional study. Vet Comp Oncol. 2018;16(1):140-147. 401 
8. Robinson WP, Elliott J, Baines SJ, Owen L, Shales CJ. Intramuscular mast cell tumors in 7 dogs. Can Vet J. 402 
2017;58(9):931-935. 403 
9. Vail DM, Michels GM, Khanna C, Selting KA, London CA. Response evaluation criteria for peripheral nodal 404 
lymphoma in dogs (v1.0)–a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp 405 
Oncol. 2010;8(1):28-37. 406 
10. Palladino S, Keyerleber MA, King RG, Burgess KE. Utility of Computed Tomography versus Abdominal 407 
Ultrasound Examination to Identify Iliosacral Lymphadenomegaly in Dogs with Apocrine Gland 408 
Adenocarcinoma of the Anal Sac. J Vet Intern Med.  2016;30(6):1858-1863.  409 
11. Griebie ER, David FH, Ober CP, et al. Evaluation of canine hepatic masses by use of triphasic computed 410 
tomography and B-mode, color flow, power, and pulsed-wave Doppler ultrasonography and correlation with 411 
histopathologic classification. Am J Vet Res. 2017;78(11):1273-1283. 412 
12. Jones ID, Lamb CR, Drees R, Priestnall SL, Mantis P. ASSOCIATIONS BETWEEN DUAL-PHASE 413 
COMPUTED TOMOGRAPHY FEATURES AND HISTOPATHOLOGIC DIAGNOSES IN 52 DOGS WITH 414 
HEPATIC OR SPLENIC MASSES. Vet Radiol Ultrasound. 2016;57(2):144-153. 415 
13. Northrup NC, Harmon BG, Gieger TL, et al. Variation among pathologists in histologic grading of canine 416 
cutaneous mast cell tumors. J Vet Diagn Invest. 2005;17(3):245-248. 417 
14. Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous 418 
Mast Cell Tumors to More Accurately Predict Biological Behavior:. Vet Pathol.  2010;48(1):147-155.  419 
15. Krick EL, Billings AP, Shofer FS, Watanabe S, Sorenmo KU. Cytological lymph node evaluation in dogs with 420 
mast cell tumours: association with grade and survival. Vet Comp Oncol.2009;7(2):130-138. 421 
16. Weishaar KM, Thamm DH, Worley DR, Kamstock DA. Correlation of Nodal Mast Cells with Clinical Outcome in 422 
Dogs with Mast Cell Tumour and a Proposed Classification System for the Evaluation of Node Metastasis. J 423 
Comp Pathol.  2014;151(4):329-338. 424 
17. Wisner ER, Zwingenberger AL. Hepatobiliary disorders. In: Atlas of Small Animal CT and MRI. Vol 228. Atlas 425 
of Small Animal CT and MRI. Chichester, UK: John Wiley & Sons, Ltd; 2017:522-537.  426 
18. O'Keefe DA. Canine Mast Cell Tumors. Vet Clin North Am:  Small Animal Practice. 1990;20(4):1105-1115. 427 
19. Taylor F, Gear R, Hoather T, Dobson J. Chlorambucil and prednisolone chemotherapy for dogs with inoperable 428 
mast cell tumours: 21 cases. J Small Anim Pract. 2009;50(6):284-289. 429 
20. Weisse C, Shofer FS, Sorenmo K. Recurrence Rates and Sites for Grade II Canine Cutaneous Mast Cell 430 
Tumors Following Complete Surgical Excision. J Am Anim Hosp Assoc. 2002;38(1):71-73. 431 
21. Hume CT, Kiupel M, Rigatti L, et al. Outcomes of Dogs with Grade 3 Mast Cell Tumors: 43 Cases (1997–432 
2007).  J Am Anim Hosp Assoc. 2011;47(1):37-44.  433 
22. Takeuchi Y, Fujino Y, Watanabe M, et al. Validation of the prognostic value of histopathological grading or c-kit 434 
mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Vet J. 2013;196(3):492-498.  435 
23. Scarpa F, Sabattini S, Bettini G. Cytological grading of canine cutaneous mast cell tumours. Vet Comp Oncol. 436 
2014;14(3):245-251. 437 
24. Book AP, Fidel J, Wills T, et al.. Correlation of ultrasound findings, liver and spleen cytology, and prognosis in 438 
the clinical staging of high metastatic risk canine mast cell tumors. Vet Radiol Ultrasound. 2011;52(5):548-554. 439 
25. Beukers M, Grosso FV, Voorhout G. Computed tomographic characteristics of presumed normal canine 440 
abdominal lymph nodes. Vet Radiol Ultrasound. 2013;50(6).  441 
26. Warland J, Amores-Fuster I, Newbury W, Brearley M, Dobson J. The utility of staging in canine mast cell 442 
tumours. Vet Comp Oncol. 2012;12(4):287-298. 443 
27. Mullins MN, Dernell WS, Withrow SJ, et al. Evaluation of prognostic factors associated with outcome in dogs 444 
with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases 445 
(1998-2004). J Am Vet Med Assoc. 2006;228(1):91-95. 446 
28. Patnaik AK, Ehler WJ, MacEwen EG. Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival 447 
Time in 83 Dogs. Vet Pathol.  2016;21(5):469-474. 448 
29. Sabattini S, Scarpa F, Berlato D, Bettini G. Histologic grading of canine mast cell tumor: is 2 better than 3? Vet 449 
Pathol. 2015;52(1):70-73. 450 
30. Mukaratirwa S. Prognostic and predictive markers in canine tumours: Rationale and relevance. A review. Vet 451 
Q. 2005;27(2):52-64. 452 
31. Seguin B, Leibman NF, Bregazzi VS, et al. Clinical outcome of dogs with grade-II mast cell tumors treated with 453 
surgery alone: 55 cases (1996-1999). J Am Vet Med Assoc. 2001;218(7):1120-1123. 454 
32. Finora K, Leibman NF, Fettman MJ, et al. Cytological comparison of fine-needle aspirates of liver and spleen 455 
of normal dogs and of dogs with cutaneous mast cell tumours and an ultrasonographically normal appearing 456 
liver and spleen. Vet Comp Oncol.2006;4(3):178-183. 457 
33. Fife WD, Samii VF, Drost WT, Mattoon JS, Hoshaw-Woodard S. Comparison Between Malignant and 458 
Nonmalignant Splenic Masses in Dogs using Contrast-Enhanced Computed Tomography. Vet Radiol 459 
Ultrasound. 2004;45(4):289-297. 460 
34. Rebhun RB, Thamm DH. Multiple Distinct Malignancies in Dogs: 53 Cases.  J Am Vet Med Assoc.  461 
2010;46(1):20-30. 462 
 463 
  464 
Table 1. Location of the primary MCT in the five patients with positive liver and spleen metastasis and corresponding 465 
regional lymph node metastasis based on cytological and/or histologic examination 466 
Location Grade Lymph node metastasis Confirmed by 
Cutaneous right pinna High Left Pre-scapular Histology 
Cutaneous ventral thorax Low Not Confirmed 
 
Cutaneous ventral thorax High Left Medial Iliac and Inguinal Cytology and Histology 
Cutaneous right scapula High Not Confirmed 
 
Cutaneous right pinna Low Not Confirmed 
 
 467 
  468 
Table 2. Hepatic CT findings for all exams (both negative and positive for metastasis) with nodular/mass lesions 469 
Breed Age Sex Neuter 
status 
Liver/Spleen 
Metastasis 
Description of mass/nodules/focal 
heterogeneity 
X Breed 11y10m Male       Neutered Negative 1 and 1.5cm hyperattenuating nodules 
X Breed 6y Female     Neutered Negative 0.54cm hyperattenuating nodule - right dorsal liver 
German 
Short-Haired 
Pointer 
8y5m Male       Neutered Negative 2.37cm hypoattenuaing nodule with mild 
peripheral enhancement 
Shar-Pei 8y Male       Neutered Negative 0.72cm Hypoattenuating nodule  
X Breed 11y Female     Neutered Positive Multiple hypoattenuating heterogenous nodules 
Lurcher 12y1m Male       Entire Negative 1.2 cm hypoattenuating nodule 
Lurcher 11y1m Male       Entire Negative Multiple small hypoattenuating nodules 
X Breed 11y4m Female     Neutered Negative Large heterogeneous liver mass 
English 
Springer 
Spaniel 
11y9m Male       Neutered Negative 1cm hypoattenuating area in cranial liver, 1.7 - 
0.8cm contrasting enhancing nodules in left liver 
Labrador 7y7m Male       Entire Negative Small contrast enhancing nodule in quadrate lobe 
Labrador 
Retriever 
8y10m Female     Neutered Negative 1.4cm and 1cm poorly defined hypoattenuating 
focal lesions 
West Highland 
White Terrier 
10y5m Female     Entire Negative 3.4cm heterogeneous mass lesion of mixed 
attenuation 
 470 
  471 
Table 3. Splenic CT findings for all exams (both Negative and Positive for Metastasis) with nodular/mass lesions 472 
Breed Age Sex Neuter 
status 
Liver or 
Spleen 
Metastasis 
Description of mass/nodules/focal 
heterogeneity 
X Breed 10y Male       Entire Negative Multiple contrast enhancing focal areas 
Beagle 6y7m Female     Neutered Negative Multiple contrast enhancing focal areas 
Shar-Pei 6y7m Male       Entire Negative Multiple contrast enhancing focal areas 
Boxer 9y6m Female     Neutered Positive 1.8cm hypoattenuating nodule on head of spleen 
and multiple others. 
X Breed 10y1m Male       Entire Positive Multiple hypoattenuating nodules 
Jack Russell 
Terrier 
10y2m Male       Neutered Negative Multiple contrast enhancing focal areas 
Staffordshire 
Bull Terrier 
7y10m Male       Entire Negative 2.2 cm mass in spleen 
X Breed 11y10m Male       Neutered Negative Multiple contrast enhancing focal areas 
German 
Short-Haired 
Pointer 
8y5m Male       Neutered Negative Multiple contrast enhancing focal areas 
Shar-Pei 8y Male       Neutered Negative 1.1cm hypoattenatuing mass.  
X Breed 11y Female     Neutered Negative One 2.3cm hypoattenuating mass, multiple focal 
hyperattenuating nodules 
Lurcher 11y10m Male       Entire Negative Multiple hypoattenuating focal areas 
Lurcher 12y1m Male       Entire Negative Multiple hypoattenuating focal areas 
Labrador 
Retriever 
8y10m Female     Neutered Negative Multiple contrast enhancing focal areas 
 473 
 474 
 475 
 476 
 477 
Table 4. Liver and spleen CT findings for dogs with positive liver and spleen MCT metastasis 478 
a. Attenuation (1 - homo, 2 - hetero diffuse, 3 - focal hetero/nodules/masses) 479 
b. Size (1 – normal, 2 enlarged) 480 
c. Lymph node size (0 – not visible) 481 
* Statistically significant  482 
  483 
Liver 
(a) 
Liver 
(b) 
Liver 
Mass/Nodules 
Positive for 
metastasis 
(YES/NO) 
L 
Hepatic 
(mm) 
(c) 
R 
Hepatic 
(mm) 
(c) 
Spleen 
(a) 
Spleen 
(b) * 
Spleen 
Mass/Nodules 
Splenic 
(mm) (c) 
Positive for 
metastasis 
(YES/NO) 
1 1 
 
YES 7.3 5.6 3 2 1.8cm 
hypoattenuating 
nodule + others. 
7.7 YES 
1 1 Hepatic cyst NO 10 9.7 3 2 Multiple 
hypoattenuating 
nodules 
6.3 YES 
3 2 3.4 cm 
hyperattenuatin
g mass lesion 
NO 0 0 2 2  4.9 YES 
1 1 
 
YES 6.2 7 1 2  4.3 YES 
1 1 
 
YES 4.4 4.6 2 1  3.1 YES 
 484 
Figure 1. Flow chart of CT examination findings according to organ examined and corresponding numbers of exams 485 
with positive metastatic MCT cytology 486 
Figure 2. Transverse plane post-contrast CT of (A) multifocal hypoattenuating splenic changes (arrows) in a dog with 487 
splenic aspirates positive for mast cell metastasis and (B) a dog with normal CT appearance of the spleen (arrow) with 488 
splenic aspirates positive for mast cell metastasis.  Patient A also shows non-related chronic degenerative right renal 489 
changes.  490 
Figure 3. Transverse plane post-contrast CT of (A) diffusely heterogeneous hepatic changes (arrows) in a dog with 491 
hepatic aspirates positive for mast cell metastasis and (B) a normal CT appearance of the liver in a dog positive for 492 
mast cell metastasis.  493 
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